chartexchange

Kyntra Bio Inc Reports Q3 2026 Earnings: Revenue of $1.76 Million and EPS of $0.04 Beat Estimates

GuruFocus | Nov 16, 2026 5:03 PM EST

Royalty Obligation Cut, FG-3246 Discontinued, Roxadustat Phase 3 Targeted for 1Q 2027 Related Stocks: KYNB ,

Read original article